Latest news with #PHAXIAM
Yahoo
2 days ago
- Business
- Yahoo
PHAXIAM Therapeutics: New Postponement of the Offer Review Hearing
LYON, France, June 05, 2025--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial infections, announces that the Lyon Commercial Court ("Tribunal des activités économiques de Lyon") decided, during a hearing held on June 4, 2025, to postpone the offer review hearing and has set a new hearing date for Wednesday, June 11, 2025. At the end of the bid examination hearing, whether a bid is accepted or not, the Lyon Commercial Court will in any case soon pronounce the conversion of the judicial reorganization into judicial liquidation. In this context, the Company will request the delisting of PHAXIAM shares from Euronext. Furthermore, PHAXIAM draws investors' attention to the fact that, given the Company's level of indebtedness, the disposal proceeds received in the event a bid is adopted would not allow for any reimbursement of shareholders. About PHAXIAM Therapeutics PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR001400K4B1, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. For more information, please visit View source version on Contacts PHAXIAM Thibaut du Fayet CEO+33 4 78 74 44 38investors@ NewCap Mathilde Bohin / Dušan Orešanský Investor RelationsArthur RouilléMedia Relations+33 1 44 71 94 94phaxiam@
Business Wire
2 days ago
- Business
- Business Wire
PHAXIAM Therapeutics: New Postponement of the Offer Review Hearing
LYON, France--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial infections, announces that the Lyon Commercial Court ('Tribunal des activités économiques de Lyon') decided, during a hearing held on June 4, 2025, to postpone the offer review hearing and has set a new hearing date for Wednesday, June 11, 2025. At the end of the bid examination hearing, whether a bid is accepted or not, the Lyon Commercial Court will in any case soon pronounce the conversion of the judicial reorganization into judicial liquidation. In this context, the Company will request the delisting of PHAXIAM shares from Euronext. Furthermore, PHAXIAM draws investors' attention to the fact that, given the Company's level of indebtedness, the disposal proceeds received in the event a bid is adopted would not allow for any reimbursement of shareholders. About PHAXIAM Therapeutics PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR001400K4B1, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. For more information, please visit
Business Wire
22-05-2025
- Business
- Business Wire
PHAXIAM Therapeutics: Postponement of the Offer Review Hearing
LYON, France--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial infections, announces that the Lyon Commercial Court ('Tribunal des activités économiques de Lyon') decided, during a hearing held on May 21, 2025, to postpone the offer review hearing and has set a new hearing date for Wednesday, June 4, 2025. At the end of the bid examination hearing, whether a bid is accepted or not, the Lyon Commercial Court will in any case soon pronounce the conversion of the judicial reorganization into judicial liquidation. In this context, the Company will request the delisting of PHAXIAM shares from Euronext. Furthermore, PHAXIAM draws investors' attention to the fact that, given the Company's level of indebtedness, the disposal proceeds received in the event a bid is adopted will likely not allow for any reimbursement of shareholders. About PHAXIAM Therapeutics PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR001400K4B1, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. For more information, please visit
Business Wire
05-05-2025
- Business
- Business Wire
PHAXIAM Therapeutics: Extension of the Observation Period of the Receivership Procedure
LYON, France--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial infections, announces the continuation of its observation period under the receivership procedure. The Commercial Court of Lyon decided on April 30, 2025 to extend the observation period and set the bid review hearing on May 21, 2025. This extension of the observation period will enable potential buyers to improve their offers. As a reminder, whether or not a bid is accepted, the Commercial Court of Lyon will in any case soon pronounce the judicial liquidation of the Company. In this context, the Company will request the delisting of PHAXIAM shares from Euronext. About PHAXIAM Therapeutics PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR001400K4B1, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. For more information, please visit
Business Wire
24-04-2025
- Business
- Business Wire
PHAXIAM Therapeutics: Update on the Receivership Procedure
LYON, France--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial infections, announces that it has received two bids as part of a disposal plan, following the bidding process (appel d'offres) launched within the framework of the receivership procedure opened on March 6, 2025. At this stage, these two offers are not yet admissible. In this context, the court-appointed administrator (administrateur judiciaire) has filed a request to convert the proceedings into judicial liquidation. The coming days will determine whether the bids can be made admissible or whether judicial liquidation must be pronounced swiftly in order to avoid further deterioration of the Company's cash position. As a reminder, whether or not a bid is accepted, the Commercial Court of Lyon will in any case soon pronounce the judicial liquidation of the Company. In this context, the Company will request the delisting of PHAXIAM shares from Euronext. Furthermore, PHAXIAM draws investors' attention to the fact that, given the Company's level of indebtedness, the proceeds from any disposal, should a takeover bid be accepted, will most likely not allow for any repayment to shareholders. About PHAXIAM Therapeutics PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR001400K4B1, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
